Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects

University of Toronto

$128,125.00

Advanced Bioreactors for Evaluation and Systematic Optimization of Decellularization and Recellularization of the Lung and Trachea

EF 2018-19

Résumé
Diseases affecting the airways are an important clinical problem and for the majority of*patients with end-stage disease, transplantation of lung and/or trachea has become the only*life-saving option. Ideally we need access to off-the-shelf replacement grafts reducing the*dependency on donor organs, wait-time and risk of death. In the lung, organ regeneration is*achieved by using biohybrid devices with partially synthetic or natural scaffolds. The approach*is to utilize advanced bioreactors operating under optimized physiological conditions to*repopulate with new cells, scaffolds in which the resident cells have been removed, and use*for functional replacement of damaged tissue. While transplantation of regenerated whole*lungs is a far-off goal, we exploit the simpler system of the trachea with which we have*extensive expertise while addressing key issues that will set the foundation for future clinical*application of whole lung grafts. At the end of the funding period, we expect to begin clinical*translation of a functional tracheal biograft used to address small airway and larger tracheal*defects, respectively. The optimized tracheal bioreactors developed can result in commercial*products via licensing to already existing lung biotech companies or through company*creation ventures with focus on enhanced organ-specific bioreactors. In addition, the*development of a computational model of fluid flow using a computerized geometrical models*of vascular (and airway) networks will allow in silico experimental programs to explore*strategies for targeted cell delivery. Models developed here have the potential for significant*impact in lung tissue engineering, and can be applied to research groups focused on other*organs. Completion of this work will set in motion a therapeutic strategy with the potential to*save lives and vastly improve the quality of life of Canadians suffering from end-stage lung*disease.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
523396-2018
Name nom
Amon, Cristina
Department département
Mechanical and Industrial Engineering
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
128125
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
1
Nb partie
1
Application title
Advanced Bioreactors for Evaluation and Systematic Optimization of Decellularization and Recellularization of the Lung and Trachea
Keyword
NSERC
Application summary
Diseases affecting the airways are an important clinical problem and for the majority of*patients with end-stage disease, transplantation of lung and/or trachea has become the only*life-saving option. Ideally we need access to off-the-shelf replacement grafts reducing the*dependency on donor organs, wait-time and risk of death. In the lung, organ regeneration is*achieved by using biohybrid devices with partially synthetic or natural scaffolds. The approach*is to utilize advanced bioreactors operating under optimized physiological conditions to*repopulate with new cells, scaffolds in which the resident cells have been removed, and use*for functional replacement of damaged tissue. While transplantation of regenerated whole*lungs is a far-off goal, we exploit the simpler system of the trachea with which we have*extensive expertise while addressing key issues that will set the foundation for future clinical*application of whole lung grafts. At the end of the funding period, we expect to begin clinical*translation of a functional tracheal biograft used to address small airway and larger tracheal*defects, respectively. The optimized tracheal bioreactors developed can result in commercial*products via licensing to already existing lung biotech companies or through company*creation ventures with focus on enhanced organ-specific bioreactors. In addition, the*development of a computational model of fluid flow using a computerized geometrical models*of vascular (and airway) networks will allow in silico experimental programs to explore*strategies for targeted cell delivery. Models developed here have the potential for significant*impact in lung tissue engineering, and can be applied to research groups focused on other*organs. Completion of this work will set in motion a therapeutic strategy with the potential to*save lives and vastly improve the quality of life of Canadians suffering from end-stage lung*disease.